Amylyx Drug Slows ALS Progression, Filings Imminent
Small Private Firm Plans To Commercialize On Its Own
Amylyx has raised just $75m to date, but that was enough to develop AMX0035 through a Phase II/III trial in which the drug slowed the progression of amyotrophic lateral sclerosis versus placebo.
